Galapagos NV

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 18 November 2008 - Galapagos NV (Euronext: GLPG) announced today new collaboration agreements with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. Total value of the contracts for Galapagos is €1.1 million over one year.

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 14 November 2008 - Galapagos NV (Euronext: GLPG) announces today that third quarter 2008 operational and financial results were in line with management expectations. These results encourage the Company to retain full year 2008 financial guidance given earlier this year.

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 5 November 2008 - Galapagos NV (Euronext: GLPG) announces today that it has completed the sale of its BioFocus DPI chemistry facility in San Diego to ChemVentures Pty Ltd, an Australian discovery research group. Financial terms were not disclosed.

Galapagos NV (EBR:GLPG) Mechelen, Belgium and Los Angeles, USA; 29 October 2008 - Galapagos NV (Euronext: GLPG) and CHDI Foundation, Inc., a non-profit organization pursuing treatments for Huntington's disease (HD), announced today new collaboration agreements focused on developing novel assays for drug discovery and evaluating known compounds as potentially new therapeutic approaches for HD. Total value of the contracts for Galapagos is $1 million (€0.8 million) over 1.5 years.

Galapagos NV (EBR:GLPG) Results to be presented today at the 2008 American College of Rheumatology Annual Scientific Meeting in San Francisco, USA

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 30 September 2008 - Galapagos NV (Euronext: GLPG) announced today that it has received a transparency notification from Delta Lloyd, disclosing that they hold a 5.4% interest in the share capital of Galapagos.

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 15 September 2008 - Galapagos NV (Euronext: GLPG) published today information as required by the new transparency legislation (Belgian Act of 2 May 2007).

Galapagos NV (EBR:GLPG) Mechelen, Belgium and Cambridge, UK; 26 August 2008 - Galapagos NV (Euronext: GLPG) and Sareum Holdings plc (AIM: SAR) announce today that Galapagos has acquired Sareum's assets in drug discovery services, for a total cash consideration of €695,000 (£553,000). These assets will position Galapagos' service division BioFocus DPI strongly in the growing field of structure-based drug discovery.

Galapagos NV (EBR:GLPG) Mechelen, Belgium; 12 August 2008 - Galapagos NV (Euronext: GLPG) announced today that its service division BioFocus DPI and UCB have signed a contract for the provision of chemistry services in the UK by BioFocus DPI, for one of UCB's medicinal chemistry programs. The total contract value for Galapagos could potentially exceed €4 M. Additionally, Galapagos is eligible to receive up to €500,000 in success payments subject to fulfillment of certain conditions.

Galapagos NV (EBR:GLPG) * Revenues increased to €33.6 M (from €25.9 M, +30%) * Net loss reduced to €9.4 M (from €16.7 M, - 44%) * BioFocus DPI revenues of €23.7 M, on track to profitability in '08 * Cash position of €27.4 M on 30 June 2008 * Completed Nanocort® clinical Phase I/II for flares in rheumatoid arthritis * Solid progress in bone & joint development programs * No need to raise additional capital in the coming 18 months